Measurement of plasma-derived substance P: Biological, methodological, and statistical considerations

Clinical and Vaccine Immunology

Volumn 13, Issue 11, 2006, Pages 1197-1203

  Campbell, Donald E ^a   Raftery, Nancy ^a   Tustin III, Richard ^a   Tustin, Nancy B ^a   DeSilvio, Michelle L ^a,b   Cnaan, Avital ^a,b   Aye, Pyone Pyone ^c   Lackner, Andrew A ^c   Douglas, Steven D ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN; SUBSTANCE P;

ANALYTIC METHOD; ARTICLE; BIOLOGICAL ACTIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; STATISTICAL PARAMETERS; ANIMAL; BLOOD; METHODOLOGY; PHYSIOLOGY; STATISTICS;

ANIMALS; HUMANS; IMMUNOENZYME TECHNIQUES; MACACA MULATTA; SUBSTANCE P;

EID: 34248648154     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00174-06     Document Type: Article

References (40)

1. Anichini, M., S. Cesaretti, M. Lepori, S. Maddali Bongi, M. Maresca, and M. Zoppi. 1997. Substance P in the serum of patients with rheumatoid arthritis. Rev. Rhum. Engl. Ed. 64:18-21.
2. Bland, J. M., and D. G. Altman. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i:307-310.
3. Bland, J. M., and D. G. Altman. 2003. Applying the right statistics: analyses of measurement studies. Ultrasound Obstet. Gynecol. 22:85-93.
4. Bondy, B., T. C. Baghai, C. Minov, C. Schule, J. M. Schwarz, P. Zwanzger, R. Rupprecht, and J.-H. Moller. 2003. Substance P serum levels are increased in major depression: preliminary results. Biol. Psychiatry 53:538-542.
5. Bost, K. L. 2004. Tachykinin-mediated modulation of the immune response. Front. Biosci. 9:3331-3332.
6. Bozic, C. R., B. Lu, U. E. Hopken, C. Gerard, and N. P. Gerard. 1996. Neurogenic amplification of immune complex inflammation. Science 273:1722-1725.
7. Campbell, W. B., O. B. Holland, C. E. Gomez-Sanchez, R. M. Graham, W. A. Pettinger, and A. C. White. 1981. Plasma substance P levels in normotensive and hypertensive subjects. Clin. Exp. Hypertens. 3:183-193.
8. Chang, M. M., S. E. Leeman, and H. D. Niall. 1971. Amino acid sequence of substance P. Nat. New Biol. 232:86-87.
9. Clark, J. W., P. D. Senanayake, G. D. Solomon, and C. Gallagher. 1994. Substance P: correlation of CSF and plasma levels. Headache 34:261-264.
10. Corbally, N., D. Powell, and K. F. Tipton. 1990. The binding of endogenous and exogenous substance-P in human plasma. Biochem. Pharmacol. 39:1161-1166.
11. Dionne, R. A., S. M. Max, S. M. Gordon, S. Parada, C. Sang, R. H. Gracly, N. F. Sethna, and D. B. MacLean. 1998. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin. Pharmacol. Ther. 64:562-568.
12. Douglas, S. D., W.-Z. Ho, D. R. Gettes, A. Cnaan, H. Zhao, J. Leserman, J. M. Petitto, R. N. Golden, and D. L. Evans. 2001. Elevated substance P levels in HIV-infected men. AIDS 15:2043-2045.
13. Faulhaber, H. D., R. Rathsack, G. Rostock, V. Homuth, D. Pfeiffer, E. Naumann, W. Hartrodt, R. C. Gorne, and P. Oehme. 1983. Evidence of decreased plasma substance P levels in human essential hypertension and influence of prazosin treatment. Biomed. Biochim. Acta 42:1019-1025.
14. Fehder, W. P., W.-Z. Ho, D. E. Campbell, W. W. Tourtellotte, L. Michaels, J. R. Cutilli, M. Uvaydova, and S. D. Douglas. 1998. Development and evaluation of a chromatographic procedure for partial purification of substance P with quantitation by an enzyme immunoassay. Clin. Diagn. Lab. Immunol. 5:303-307.
15. Fehder, W. P., J. Sachs, M. Uvaydova, and S. D. Douglas. 1997. Substance P as an immune modulator of anxiety. Neuroimmunomodulation 4:42-48.
16. Fernandez-Rodriguez, C. M., J. Prieto, J. Quiroga, J. M. Zozoya, A. Andrade, M. Nunez, B. Sangro, and J. Penas. 1995. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion. Hepatology 21:35-40.
17. Ho, W.-Z, and S. D. Douglas. 2004. Substance P and neurokinin-1 receptor modulation of HIV. Neuroimmunology 157:48-55.
18. Hortnagl, H., E. A. Singer, K. Lenz, G. Klienberger, and H. Lochs. 1984. Substance P is markedly increased in plasma of patients with hepatic coma. Lancet i:480-483.
19. Kramer, H. J., R. Dusing, H. Stelkens, R. Heinrich, J. Kipnowski, and K. Glanzer. 1980. Immunoreactive substance P in human plasma: response to changes in posture and sodium balance. Clin. Sci. 59:75-77.
20. Kramer, M. S., N. Cutler, J. Feighner, R. Shrivastava, J. Carman, J. J. Sramek, S. A. Reines, G. Liu, D. Snavely, E. Wyatt-Knowles, J. J. Hale, S. G. Mills, M. MacCoss, C. J. Swain, T. Harrison, R. G. Hill, F. Hefti, E. M. Scolnick, M. A. Cascieri, G. G. Chicchi, S. Sadowski, A. R. Williams, L. Hewson, D. Smith, E. J. Carlson, R. J. Hargreaves, and N. M. J. Rupniak. 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
21. Kukuvitis, A., A. Kourtis, N. Papaiconomou, V. Zournatzi, G. Makedos, and D. Panidis. 2003. Differential effects of unopposed versus opposed hormone therapy, tibolone, and raloxifene on substance P levels. Fertil. Steril. 80:96-98.
22. Kunt, T., T. Forst, S. Schmidt, A. Pfutzner, S. Schneider, O. Harzer, M. Lobig, M. Engelbach, K. Goitom, T. Pohlmann, and J. Beyer. 2000. Serum levels of substance P are decreased in patients with type 1 diabetes. Exp. Clin. Endocrinol. Diabetes 108:164-167.
23. Lee, F. Y., H. C. Lin, Y. T. Tsai, F. Y. Chang, R. H. Lu, M. C. Hou, C. P. Li, C. J. Chu, S. S. Wang, and S. D. Lee. 1997. Plasma substance P levels in patients with liver cirrhosis: relationship to systemic and portal hemodynamics. Am. J. Gastroenterol. 92:2080-2084.
24. Lotti, T., G. Hautmann, and E. Panconesi. 1995. Neuropeptides in skin. J. Am. Acad. Dermatol. 33:482-496.
25. Mantyh, C. R., T. S. Gates, R. P. Zimmerman, M. L. Welton, E. P. Passaro, Jr., S. R. Vigna, J. E. Maggio, L. Kruger, and L. W. Mantyh. 1988. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc. Natl. Acad. Sci. USA 85:3235-3239.
26. Marshall, K. W., B. Chiu, and R. D. Inman. 1990. Substance P and arthritis: analysis of plasma and synovial fluid. Arthritis Rheum. 33:87-90.
27. McGillis, J. P., M. Mitsuhashi, and D. G. Payan. 1990. Immunomodulation by tachykinin neuropeptides. Ann. N. Y. Acad. Sci. 594:85-94.
28. McLean, S. 2005. Do substance P and the NK1 receptor have a role in depression and anxiety. Curr. Pharm. Des. 11:1529-1547.
29. Michaels, L. A., K. Ohene-Frempong, H. Zhao, and S. D. Douglas. 1998. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood 92:3148-3151.
30. Navari, R. M., R. R. Reinhardt, R. J. Gralla, M. G. Kris, P. J. Hesketh, A. Khojasteh, H. Kindler, T. H. Grote, K. Pendergrass, S. M. Grunberg, A. D. Carides, B. J. Gertz, et al. 1999. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N. Engl. J. Med. 340:190-195.
31. Nicoll, R. A., C. Schenker, and S. E. Leeman. 1980. Substance P as a neurotransmitter candidate. Annu. Rev. Neurosci. 3:227-268.
32. Otsuka, M., and T. Takahashi. 1977. Putative peptide neurotransmitters. Annu. Rev. Pharmacol. Toxicol. 17:425-439.
33. Otsuka, M., and K. Yoshioka. 1993. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73:229-308.
34. 1 receptors in progression of human gliomas. Life Sci. 67:985-1001.
35. Reynolds, W. J., B. Chiu, and R. D. Inman. 1988. Plasma substance P levels in fibrositis. J. Rheumatol. 15:1802-1803.
36. Rissler, K. 1995. Sample preparation, high-performance liquid chromatographic separation and determination of substance P-related peptides. J. Chromatogr. B 665:233-270.
37. Rupniak, N. M. J. 2002. New insights into the antidepressant actions of substance P (NK-1 receptor) antagonists. Can. J. Physiol. Pharmacol. 80:489-494.
38. Singh, D., D. D. Joshi, M. Hameed, J. Qian, P. Gascon, B. P. Maloof, A. Mosenthal, and P. Rameshwar. 2000. Increased expression of preprotachykinin-1 and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc. Natl. Acad. Sci. USA 97:388-393.
39. Tripp, R. A., A. Barskey, L. Goss, and L. J. Anderson. 2002. Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. J. Neuroimmunol. 129:141-153.
40. Weinstock, J. V., A. Blum, A. Metwali, D. Elliott, and R. Arsenescu. 2003. IL-18 and IL-12 signal through the NF-kappa B pathway to induce NK-1R expression on T cells. J. Immunol. 170:5003-5007.